HeartFlow Stock

heartflow.comHealthcare / Healthcare providers & servicesFounded: 2007Funding to Date: $528.72MM

HeartFlow is revolutionizing precision heart care, combining human ingenuity with advanced AI technology. They began their journey to improve coronary artery disease diagnosis with FFRCT and have now expanded their product portfolio to include anatomic stenosis and plaque information. This company was founded by Charles Taylor, Christopher Zarins, and John Stevens in 2007 and is headquartered in Redwood City, CA.

Register To Buy and Sell Shares

For more details on financing and valuation for HeartFlow, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access HeartFlow’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like HeartFlow.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

HeartFlow investors also invested in these private companies


Management Team

Campbell Rogers MD
Chief Medical Officer & Executive Vice President
Charles Taylor Ph.D
Co-Founder, Chief Scientific Officer & Board Member
Noemi Espinosa JD
Chief Ethics & Compliance Officer & General Counsel
Christopher Zarins MD
Co-Founder, Senior Advisor on Clinical Science & Senior Vice President of Medical Affairs
John Farquhar
Chief Executive Officer, President & Board Member
Monica Tellado
Chief Financial Officer

Board Members

Jeffrey Lightcap
HealthCor Partners Management
Casey Tansey
US Venture Partners
Barry Uphoff
Capricorn Investment Group

Frequently Asked Questions About HeartFlow’s Stock

Can you buy HeartFlow’s stock?
HeartFlow is not publicly traded on NYSE or NASDAQ in the U.S. To buy HeartFlow’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell HeartFlow’s stock?
Yes, you can sell stock of a private company like HeartFlow. Forge can help you sell your HeartFlow stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is HeartFlow’s stock price?
HeartFlow is a privately held company and therefore does not have a public stock price. However, you may access HeartFlow’s private market stock price with Forge Data.
What is HeartFlow’s stock ticker symbol?
HeartFlow does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Top Five Digital Health Technologies in 2019
For 2019, we asked companies around the world one basic question: “Please indicate the key technology which you believe will have the most profound impact on the healthcare industry during 2019?” The results are not very surprising:
Why HeartFlow’s Data From This Weekend Don’t Change Anything
The $1.5 billion health-tech startup HeartFlow has a noninvasive test for heart disease based on machine learning analysis of CT scans. Two new studies are unlikely to win over its critics.
HeartFlow Has Raised $500 Million For A Test To Detect Heart Disease. Does It Make Patients Better Off?
The valuation is based on a big idea: a noninvasive test that peers into a patient’s coronary arteries to see how blocked they are.
Updated on: May 17, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.